Download PDF
Thromb Haemost 1988; 60(01): 008-012
DOI: 10.1055/s-0038-1647624
Original Article
Schattauer GmbH Stuttgart

Antithrombin III Molecular Variants with Defective Binding to Heparin or to Serine Proteases: Evidence of Two Different Abnormal Patterns Identified by Crossed Immunoelectrofocusing

G Leone
The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
,
V De Stefano
The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
,
R Ferrelli
The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
,
L Teofili
The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
,
L Tengborn
1   The Department for Coagulation Disorders, University of Lund, Malmö, Sweden
,
E Vahtera
2   The Finnish Red Cross Blood Transfusion Service, Helsinki, Finland
,
B Bizzi
The Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy
› Author Affiliations
Further Information

Publication History

Received 28 September 1987

Accepted after revision 09 March 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Molecular heterogeneity of antithrombin III (AT III) was investigated by a technique of crossed immunoelectrofocusing (CIEF) in plasma samples of patients from 16 families with AT III congenital defect, including 8 AT III molecular variants. The AT III CIEF pattern was normal in all the patients with AT III quantitative deficiency, showing a balanced decrease of all the peaks. Out of the 8 AT III variants investigated, 6 had an abnormal pattern: the three variants with defective binding to heparin (AT III Roma, AT III Barcelona, AT III Malmö) shared a similar abnormal pattern; three variants with defective binding to serine proteases (AT III Pescara, AT III Milano, AT III Tampere) had a common abnormal pattern clearly different from the first one, whereas the other two variants deficient in the inactivation of the serine proteases (AT III Chicago, AT III Milano 2) showed a normal pattern. The first type of pathological pattern (type Roma) was characterized by the presence of an abnormal peak overlapping the normal isoforms present at pH 4.8-4.6 and by an additional peak at pH 4.5. The second type of pattern (type Pescara) showed an additional peak at pH 4.5 and an abnormal quantitative distribution of the isoantithrombins all throughout the pH range (5.2-4.6). In order to separate the abnormal AT III fraction from the normal one, plasma of a patient with Roma defect and serum of a patient with Pescara defect were passed throughout an heparin-ultrogel column. The CIEF of the different AT III Roma and AT III Pescara fractions obtained by affinity chromatography confirmed that the abnormalities found in the corresponding patterns of the native samples were related to the pathological isoantithrombins only. It was concluded that the CIEF can be an useful tool to characterize abnormal antithrombins and can reveal close affinities among AT III molecular variants belonging to different subgroups according to the conventional tests.

Key words

Antithrombin III congenital deficiency - Crossed immunoelectrofocusing
 

  • References

  • 1 Barrowcliffe TW, Thomas DP. Antithrombin and heparin. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds) Churchill Livingstone; Edinburgh: 1981. pp 712-724
    Google Scholar
  • 2 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6506
    PubMedGoogle Scholar
  • 3 Sørensen PJ, Sas G, Peto I, Blaskó G, Kremmer T, Samu A. Distinction of two pathological antithrombin molecules: Antithrombin III Aalborg and Antithrombin III Budapest. Thromb Res 1982; 26: 211-219
    CrossrefPubMedGoogle Scholar
  • 4 Barbui T, Finazzi G, Rodeghiero F, Dini E. Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III Vicenza). Br J Haematol 1983; 54: 561-565
    CrossrefPubMedGoogle Scholar
  • 5 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin “Chicago”: a functionally abnormal molecule with increased affinity to heparin causing familial thrombophilia. Blood 1983; 62: 1242-1250
    PubMedGoogle Scholar
  • 6 Girolami A, Marafioti F, Rubertelli M, Vicarioto MA, Cappellato G, Mazzuccato M. Antithrombin III Trento: a “new” congenital AT III abnormality with a peculiar crossed-immunoelectrophoresis pattern in the absence of heparin. Acta Haematol 1984; 72: 73-82
    CrossrefPubMedGoogle Scholar
  • 7 Jørgensen M, Petersen LC, Thorsen S. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med 1984; 104: 245-256
    PubMedGoogle Scholar
  • 8 Aiach M, Nora M, Fiessinger JN, Roncato M, François D, Gelas MA. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Thromb Res 1985; 39: 559-570
    CrossrefPubMedGoogle Scholar
  • 9 Howarth DJ, Samson D, Stirling Y, Seghatchian MJ. Antithrombin III “Northwick Park”: a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity. Thromb Haemostas 1985; 53: 314-319
    PubMedGoogle Scholar
  • 10 Wolf M, Boyer C, Tripodi A, Meyer D, Larrieu MJ, Mannucci PM. Antithrombin III Milano: a new variant with monomeric and dimeric inactive antithrombin III. Blood 1985; 65: 496-500
    PubMedGoogle Scholar
  • 11 Sambrano JE, Jacobson LJ, Reeve EB, Manco-Johnson MJ, Hathaway WE. Abnormal antithrombin III with defective serine proteases binding (Antithrombin III “Denver”). J Clin Invest 1986; 77: 887-893
    CrossrefPubMedGoogle Scholar
  • 12 Vahtera E, Ala-Houhala I, Ikkala E, Koivunen E, Myllylä G, Rasi V. Antithrombin III “Tampere“: detection of microheterogeneity by isoelectric focusing. XXXIVth Colloquium on Protides of the Biological Fluids. Brussels 1986 Abstr. Cl.08
    PubMedGoogle Scholar
  • 13 Leone G, De StefanoV, Di DonfrancescoA, Ferrelli R, Traisci G, Bizzi B. Antithrombin III Pescara: a defective AT III variant with no alterations of plasma crossed Immunoelectrophoresis, but with an abnormal crossed immunoelectrofocusing pattern. Br J Haematol 1987; 65: 187-191
    CrossrefPubMedGoogle Scholar
  • 14 Tripodi A, Krachmalnicoff A, Mannuci PM. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Thromb Haemostas 1986; 56: 349-352
    PubMedGoogle Scholar
  • 15 Tran TH, Bounameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
    PubMedGoogle Scholar
  • 16 Wolf M, Boyer C, Lavergne JM, Larrieu MJ. A new familial variant of antithrombin III: “Antithrombin III Paris”. Br J Haematol 1982; 51: 285-295
    CrossrefPubMedGoogle Scholar
  • 17 Sakuragawa N, Takahashi K, Kondo S-I, Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 1983; 31: 305-317
    CrossrefPubMedGoogle Scholar
  • 18 Chassè JF, Esnard F, Guitton JD, Mouray H, Perigois F, Fauconneau G, Gauthier F. An abnormal plasma antithrombin III with no apparent affinity for heparin. Thromb Res 1984; 34: 297-302
    CrossrefPubMedGoogle Scholar
  • 19 Fèlez J, Grau F, Fontcuberta J, Soto R, Diego I, Rueda F, Rutilant ML. Qualitative and quantitative congenital deficiency of antithrombin III: a new molecular variant provisionally called AT III Barcelona. Thromb Haemostas 1985; 54: 90 (Abstr.)
    PubMedGoogle Scholar
  • 20 Fischer AM, Cornu P, Sternberg C, Mériane F, Dautzenberg MD, Chafa O, Beguin S, Desnos M. Antithrombin III Alger: a new homozygous AT III variant. Thromb Haemostas 1986; 55: 218-221
    PubMedGoogle Scholar
  • 21 Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemostas 1986; 56: 18-22
    PubMedGoogle Scholar
  • 22 Sas G, Blaskò G, Bànhegyi D, Jákó J, Palos AL. Abnormal antithrombin III (AT III Budapest) as a cause of familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-115
    PubMedGoogle Scholar
  • 23 Leone G, Cotumaccio R, De StefanoV, Zanetti L. Antithrombin III Roma: a familial quantitative-qualitative AT III deficiency identifiable by crossed immunoelectrofocusing and by crossed Immunoelectrophoresis. Haematologica 1983; 68: 765-774
    PubMedGoogle Scholar
  • 24 Tengborn L, Frohm B, Nilsson LE, Nilsson IM. A Swedish family with abnormal antithrombin III. Scand J Haematol 1985; 34: 412-416
    PubMedGoogle Scholar
  • 25 Sas G, Petö I, Bànhegyi D, Blaskò G, Domjàn G. Heterogeneity of the “classical” antithrombin III deficiency. Thromb Haemostas 1980; 43: 133-136
    PubMedGoogle Scholar
  • 26 Sas G. Defects in serine protease inhibitors. Thromb Haemostas 1987; 58: 248 (Abstr.)
    PubMedGoogle Scholar
  • 27 Nordenman B, Nyström C, Björk I. The size and shape of human and bovine antithrombin III. Eur J Biochem 1977; 78: 195-203
    CrossrefPubMedGoogle Scholar
  • 28 Borsodi A, Narasimhan TR. Microheterogeneity of human antithrombin III. Br J Haematol 1978; 39: 121-127
    CrossrefPubMedGoogle Scholar
  • 29 Murano G, Miller-Andersson M, Williams L. Heterogeneity of purified human antithrombin III. Thromb Res 1981; 24: 489-493
    CrossrefPubMedGoogle Scholar
  • 30 Leone G, Valori VM, Cotumaccio R, Massi G. Human antithrombin III heterogeneity: a study by isoelectrofocusing and crossed immunoelectrofocusing. Haemostasis 1983; 13: 369-373
    PubMedGoogle Scholar
  • 31 Leone G, Cotumaccio R, De StefanoV, Zanetti L, Bizzi B. Different forms of AT III congenital defect: a study by crossed immunoelectrofocusing. Scand J Haematol 1984; 33: 410-417
    PubMedGoogle Scholar
  • 32 Carrell RW, Jeppson J-O, Laurell C-B, Brennan SO, Owen MC, Vaughan L, Boswell DR. Structure and variation of human alpha-1-antitrypsin. Nature 1982; 298: 329-334
    CrossrefPubMedGoogle Scholar
  • 33 Sas G, Pepper DS, Cash JD. Investigations on antithrombin III in normal plasma and serum. Br J Haematol 1975; 30: 265-272
    CrossrefPubMedGoogle Scholar